AGAgnieszka Giza

Agnieszka Giza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Agnieszka Giza has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Radiation-Free Therapy for the Initial Treatment of Good Prognosis Early Non-Bulky Hodgkin Lymphoma, Defined by a Low Metabolic Tumor Volume and a Negative Interim PET After 2 Chemotherapy Cycles: The RAFTING Trial Protocol

    by Kateryna Filonenko, Marco Picardi, Stephane Chauvie, Andrea Riccardo Filippi, Maria Cristina Pirosa, Luca Guerra, Federico Fallanca, Marta Bednarek, Michał Kurlapski, Eva Domingo-Domenech, et al.

    Radiation-free treatment for early-stage classic Hodgkin lymphoma (eHL) has been shown to be less effective than standard combined-modality treatment (CMT; chemotherapy plus involved-node radiotherapy (INRT)), which achieves long-term disease control of 94–95%. Approximately 70% of patients can be cured with chemotherapy alone, whereas about 5% fail CMT. Identifying patients who can safely receive chemotherapy alone and those requiring intensified CMT could enable a risk-adapted treatment strategy. The RAFTING trial (NCT04866654; EudraCT 2020-002382-33) is an international, prospective, phase 2, non-inferiority study enrolling patients 18–70 years, stage I–IIA eHL without bulky disease, B symptoms, or extranodal involvement. Low-risk (LR) patients are defined by total metabolic tumor volume (TMTV) <84 mL and negative PET-2. Those with at least one modified EORTC (mEORTC) risk factor, in which bulky disease is replaced by a large nodal mass (5–10 cm), receive four ABVD cycles, while those without risk factors receive two ABVD cycles alone. High-risk (HR) patients, defined by TMTV ≥84 mL and/or positive PET-2, receive “triple therapy”: 4 ABVD cycles, INRT (20/30 Gy), and nivolumab (240 mg q2w, ≤doses). LR patients are monitored using cfDNA. Limited relapse is treated with INRT (36 Gy) and nivolumab. The RAFTING trial is the first prospective eHL study to personalize treatment using TMTV and PET-2. It aims to omit radiotherapy in LR patients, intensify treatment in HR patients, and spare relapsed LR patients high-dose chemotherapy and autologous transplantation. CfDNA is being evaluated as a relapse marker. Despite the protocol’s complexity, this study exemplifies personalized medicine and could transform treatment practices.

  • Open Access

    Primary Adrenal Gland Lymphoma: Report of 13 Cases—A Retrospective Multicenter Polish Lymphoma Research Group Analysis

    by Magdalena Witkowska, Kacper Kościelny, Agnieszka Giza, Ryszard Swoboda, Joanna Drozd-Sokołowska, Dariusz Wołowiec

    Introduction: The existence of primary adrenal gland lymphoma (PAGL) has been debated due to lack of lymphoid tissue in the adrenal glands. PAGL is extremely rare, accounting for less than 1% of all types of lymphomas. The aim of this study was to analyze patients with PAGL in Polish population. Material and Methods: We retrospectively reviewed 13 adult patients with PAGL diagnosed in Polish Hematological Centers. Results: A total of 13 patients (5 women and 8 men) with PAGL were included into the study. The median age at the diagnosis was 69.1 years (range: 31–85). The most common histological type was diffuse large B-cell lymphoma (DLBCL)-12 patients, the remaining one was diagnosed with Hodgkin lymphoma (HL). In 7 patients (54%), the left adrenal gland was involved; in 3 patients (23.5%), the right adrenal gland was involved; and 3 patients (23.5%) had bilateral lymphoma. Systemic symptoms (B symptoms) were observed in 11 out of 13 patients (85%). Two patients (15%) were treated with chemotherapy alone and the remaining eleven patients (85%) with immune and chemotherapy together (85%). During the follow-up period, 11 patients died, 8 had relapsed or refractory disease (62%), and 3 patients (23%) had relapse in central nervous system (CNS). The median progression-free survival (PFS) was 14.63 months, while the median overall survival (OS) was 20.30 months. Adrenalectomy of the involved adrenal gland was associated with shorter PFS (p = 0.0165), with trend of shorter OS. Achieving complete remission (CR) after front line treatment was associated with significantly longer OS (p = 0.0239) and PFS (p = 0.0152). Conclusions: Adrenal glands are extremely rare as primary locations of extranodal lymphoma. The prognosis of PAGL is generally poor. In this study, we described demographic, clinical, and pathological characteristics as well as factors that may affect survival among these groups. So far, it is the largest polish multicenter experience describing patients with PAGL.

  • Open Access

    Primary Renal Lymphoma: Report of 32 Cases—A Retrospective Multicenter PLRG Analysis

    by Magdalena Witkowska, Joanna Romejko-Jarosińska, Agnieszka Giza, Joanna Drozd-Sokołowska, Damian Mikulski, Janusz Hałka, Anna Morawska-Krekora, Ewa Paszkiewicz-Kozik, Kamil Wdowiak, Dariusz Wołowiec, et al.

    Introduction: Primary renal lymphoma is extremely rare, accounting for less than 1% of all lymphomas. Objectives: The aim of this study was to describe a group of patients with primary renal lymphoma diagnosed in hematology and oncology centers aligned with the Polish Lymphoma Research Group (PLRG). Patients and methods: This was a retrospective analysis of adult patients with primary renal lymphoma diagnosed at PLRG centers. Results: Thirty-two patients were diagnosed in seven centers over 24 years (2000–2023). The most common type of lymphoma was diffuse large B-cell lymphoma (DLBCL). The median progression-free survival (PFS) after first-line treatment was 2.1 (95% CI: 1.07–4.18) years, while the median overall survival (OS) was 6.3 (95% CI: 1.82–6.34) years. The median age at diagnosis was 63.3 years old, and 59.4% of the patients were females. In multivariate Cox regression for PFS, only creatinine > 1.5 mg/dL (HR 10.2, 95% CI: 2.08–50.09, p = 0.004) and hemoglobin (Hgb) < 10 g/dL (HR 8.39, 95% CI: 1.88–37.49) were associated with inferior PFS. Patients who achieved complete remission (CR) after first-line of treatment had significantly longer PFS (median 4.18, 95% CI: 2.02–4.18 vs. median 0.73, 95% CI: 0.50–0.79, p = 0.004) and OS (median not reached vs. median 1.49, 95% CI: 0.43–6.33, p = 0.001). Patients treated with nephrectomy had longer OS (median not reached vs. median 5.07, 95% CI: 1.32–5.08, p = 0.05). However, in multivariate Cox regression for OS, only hypoalbuminemia was an independent factor for inferior survival (HR 5.44, 95% CI: 1.12–26.38, p = 0.04). Conclusions: Primary renal lymphoma is an extremely rare type of lymphoma with a poor prognosis. The prognosis may improve with future advances in treatment, including nephrectomy.


  • Open Access

    Immediate Response to Brentuximab Vedotin in a Patient with Localized MF-LCT

    by Agnieszka Giza, Karol Miklusiak, Przemysław Hałubiec, Andrzej Jaworek, Dagmara Zimowska-Curyło, Grzegorz Dyduch, Tomasz Sacha

    The large cell transformation of mycosis fungoides (MF-LCT) is a phenomenon observed in the advanced stages of mycosis fungoides (MF), which is the most common primary cutaneous lymphoma. The diagnostic criteria of MF-LCT are a minimum of 25% of large cells or a formation of microscopic nodules of them in the histological examination of skin samples. The clinical outcomes for MF-LCT are poor, as less than 20% of patients survive 5 years after diagnosis, but the expression of the CD30 antigen is generally considered to be associated with a better prognosis. We present a case of a patient with the diagnosis of MF with LCT, with an ulcerated tumor lesion approximately 30 × 20 cm in size on the right lateral abdominal wall. Brentuximab vedotin (BV) treatment was started due to the presence of the CD30 antigen, with a quick and impressive regression of the cutaneous lesion and tumor mass and good treatment tolerance. After follow-up of 20 months, patient remains in complete remission. A schedule of treatment for MF-LCT is directed mainly by the clinical stage of the disease and the comorbidities; the more severe clinical course of the disease requires systemic treatment. If at least 5% of the cells found in the skin lesions biopsy sample express the CD30 antigen, a beneficial effect of BV treatment could be expected. It may seem that the use of BV is one of the optimal therapeutic options in patients with advanced MF-LCT showing expression of CD30.


  • Open Access

    Scalp skin primary cutaneous follicle center lymphoma – Case report

    by Agnieszka Giza, Tomasz Stramek, Andrzej Jaworek, Wojciech Jurczak, Aleksander Skotnicki


    • 1 January 2015
      • Vol. 72  (11) , 606-10

    Efficacy and safety of stem cell mobilization with cyclophosphamide plus etoposide versus cyclophosphamide alone.

    by Artur Jurczyszyn, David H Vesole, Joanna Gdula-Argasińska, Agnieszka Giza, Daria Zawirska, Jolanta Baster, Zbigniew Walter, Dorota Węglarska, Agnieszka Dadej, Jorge J Castillos, et al.

    The use of the combination of two cytostatics cyclophosphamide (CTX) and etoposide (VEP) and G-CSF is a reasonable alternative, especially for stem mobilization in multiple myeloma (MM) patients from countries in which newer treatments are limited due to financial constraints. The aim of this study was to compare the efficacy and safety of CTX-VEP versus CTX alone for mobilization of hematopoietic stem cells in MM patients. The analysis included 48 consecutive MM patients mobilized with CTX-VEP compared to 43 consecutive historical controls mobilized with CTX alone. The two groups of MM patients did not differ in terms of the median number of apheresis procedures, median yield the first day, median numbers of harvested CD34+ cells, proportion of patients with at least 5 x 10⁶/kg yield and incidence of non-hematological complications. The median cumulative dose of G-CSF given to individuals in the CTX-VEP group was significantly lower than in the CTX group (p < 0.001). The incidence of post-mobilization thrombocytopenia was higher in the CTX group (p 20 x 10⁹/l (10 vs. 11 days, p = 0.004) and the median time to neutrophil count > 50 x 10⁹/l (11 vs. 13 days, p < 0.001) were significantly shorter among the patients mobilized with CTX-VEP than in those treated with CTX alone. These findings suggest that CTX-VEP is as efficacious and possibly safer than CTX alone.

    • 1 January 2012
      • Vol. 69  (3) , 107-14

    [Hematological toxicity of radioimmunotherpy with 90Y Ibritumomab].

    by Wojciech Jurczak, Marta Szostek, Małgorzata Jakóbczyk, Anna Sowa Staszczak, Dagmara Zimowska-Curyło, Agnieszka Giza, Marcin Sobociński, Alicja Hubalewska-Dydejczyk, Aleksander B Skotnicki

    Radioimmunotherapy with 90Y Ibritumomabu (Zevalin, BSP) is a new method of systemic radiotherapy applicable to B-cell lymphoma patients. It may be delivered as a short outpatient procedure, with few adverse effects other than hematological toxicity. In the paper, we present length and depth of cytopenias, together with the results of additional tests performed to reveal the possible pathomechanisms, based on 102 patients treated at the University Hospital in Krakow.

    • 1 January 2012
      • Vol. 69  (5) , 171-5

    [Escalated BEACOPP as an alternative in high risk Hodgkin lymphoma].

    by Wojciech Jurczak, Dorota Krochmalczyk, Agnieszka Giza, Marcin Sobociński, Aleksander B Skotnicki

    Hodgkin Disease is one of the common lymphoma subtypes: every year over 750 new cases are diagnosed in Poland. It is most frequent in young adults between 25 - 30 years of age. In a low risk cases prognosis is excellent, and the treatment may be limited to short chemotherapy consolidated by involved field radiotherapy. In high risk cases with a large tumor burden prognosis depends from the choice of the initial therapy. Results of 8 years experience with escalated BEACOPP in UJ CM Department of Hematology are summarized in the paper. Monitoring the early response in imaging studies, particularly in positron emission tomography, allows in the majority of cases to decrease the duration of intensive therapy, without loosing it's efficacy.

    • 1 January 2008
      • Vol. 11  (1) , 5-11

    New forms of radionuclide therapy with (90)Y in oncology.

    by Alicja Hubalewska-Dydejczyk, Wojciech Jurczak, Anna Sowa-Staszczak, Jolanta Kunikowska, Leszek Krolicki, Aleksandra Gilis-Januszewska, Agnieszka Giza, Magdalena Szurkowska, Rota Pach, Bogusław Głowa, et al.

    Currently, there is growing interest in the use of the beta emitter (90)Y in systemic therapy in oncology. For successful therapy, an appropriate ligand is chosen to carry the isotope to the place of its action. As well as performing this function, the type of the ligand influences both the course and the side effects of the treatment. For RIT of lymphomas, bone marrow becomes the critical organ; in NET patients treated with labelled somatostatin analogues, increased kidney irradiation can occur. The aim of this study was to evaluate the side effects of therapy using 90Y associated with different ligands, depending on the charge to critical organs after treatment in two groups of patients: those with neuroendocrine tumours and those with non-Hodgkin's lymphomas. 32 patients with histopathologically confirmed NET treated with (90)Y-DOTATATE (7.4 GBq/m(2) cumulative dose) and 30 NHL patients treated with (90)Y-ibritumomab tiuxetan (1200 MBq max dose) were enrolled in the study. The kidney function and changes of blood indices were assessed during the course of the therapy. 59% of NET patients treated with (90)Y-DOTATATE displayed transient reduction of blood indices, the largest after cycles III and IV of therapy. After 5 months an increase in creatinine level was noticed, but no statistically important changes in creatinine level and GFR were observed. In the group of patients with NHL, the change of haematological indices after RIT concerned mainly PLT, ANC and WBC. The reduction of the average PLT and WBC values started in the first weeks after the treatment application, reaching nadir in the 6(th) week and 8(th) week, respectively. No life threatening infections were observed in either group of patients. After treatment with the use of the (90)Y radionuclide, no significant treatment toxicity, including disorders involving the critical organs for both types of therapies, was found in the groups of neuroendocrine tumour and non-Hodgkin's lymphoma patients.

    • 1 January 2007
      • Vol. 10  (2) , 91-7

    Radioimmunotherapy in follicular lymphomas, a retrospective analysis of the Polish Lymphoma Research Group's (PLRG) experience.

    by Wojciech Jurczak, Alicja Hubalewska-Dydejczyk, Agnieszka Giza, Anna Sowa-Staszczak, Tomasz Wróbel, Grzegorz Mazur, Piotr Boguradzki, Wanda Knopińska-Posłuszny, Bohdan Huszno, Aleksander B Skotnicki

    Ibritumomab is an (90)Yttrium ((90)Y) labelled radioimmunoconjugate registered to treat follicular lymphoma relapsing or refractory after Rituximab therapy. Combining the specificity of anti CD20 monoclonal antibodies with the efficacy of radiotherapy, it is particularly effective in patients with advanced stages of disease with generalized lymphadenopathy. Twenty-one patients with follicular lymphoma, after failing 2-5 lines of previous treatment, were subjected to radioimmunotherapy in three Polish Lymphoma Research Group (PLRG) centres. Ibritumomab infusion was followed by 2 doses of Rituximab (250 mg/m(2) at day -7 and 0) to enhance its biodistribution. Radioimmunoconjugate was prepared in the Nuclear Medicine Departments of participating centres based on patient weight and full blood count results (14.8 MBq/kg, max 1200 MBq, reduced to 11.1 MBq/kg in cases with blood platelet 100,000-150,000 or leukocytes 1500-2000). 14.8 MBq/kg (0.4 mCi/kg) 100 thousand to 149 thousand/mm(3) platelets 11.1 MBq/kg (0.3 mCi/kg) The primary endpoint of the study was the assessment of response rate and haematological toxicity. Objective responses were observed in all patients, with 10 partial and 12 complete regressions. Cytopenia, starting 3-4 weeks after radioimmunotherapy, reflected haematological toxicity - the only important side effect. Thrombocytopenia was more pronounced, with platelet counts of < 50,000/ul in every second patient. One patient developed myelodysplastic syndrome 21 months after the procedure. After the medium time of follow up over 2 years, 2 patients died. Median progression free survival (secondary study endpoint) was 15 months. Ibritumomab radioimmunotherapy is an efficient method of palliation treatment of heavily pre-treated follicular lymphoma patients, failing numerous previous treatment lines. Earlier application increases the number of complete responses and prolongs progression free survival.